Diflomotecan, a promising homocamptothecin for cancer therapy

Expert Opinion on Investigational Drugs

Volumn 18, Issue 1, 2009, Pages 69-75

  Kroep, Judith R ^a   Gelderblom, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Camptothecin; Diflomotecan; Homocamptothecin; Review; Topoisomerase I

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; DIFLOMOTECAN; DOXORUBICIN; IRINOTECAN; LURTOTECAN; TOPOTECAN;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EX VIVO STUDY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PROSTATE CANCER; REVIEW; THROMBOCYTOPENIA;

ANIMALS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 67649373026     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802571674     Document Type: Review

References (48)

1. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361:2235-2242
2. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-1726 (Pubitemid 18100142)
3. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989;28:4629-4638 (Pubitemid 19151036)
4. Kjeldsen E, Svejstrup JQ, Gromova II, et al. Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. J Mol Biol 1992;228:1025-1030 (Pubitemid 23018485)
5. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I - targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-1048 (Pubitemid 20010531)
6. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994;54:539-546 (Pubitemid 24053198)
7. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972;56:95-101
8. ten Bokkel HW, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193
9. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626-4633 (Pubitemid 46224065)
10. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91 (Pubitemid 34438898)
11. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418 (Pubitemid 28510874)
12. Perez EA, Hillman DW, Mailliard JA, et al. Randomized Phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 2004;22:2849-2855 (Pubitemid 41079903)
13. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729 (Pubitemid 350086473)
14. Burkart C, Bokemeyer C, Klump B, et al. A Phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res 2007;27:2845-2848 (Pubitemid 47228008)
15. Burke TG. Chemistry of the camptothecins in the bloodstream. Drug stabilization and optimization of activity. Ann NY Acad Sci 1996;803:29-31
16. Burke TG, Mi Z. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem 1993;36:2580-2582 (Pubitemid 23270812)
17. Lavergne O, Lesueur-Ginot L, Pla Rodas F, et al. BN 80245: an E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg Med Chem Lett 1997;7:2235-2238 (Pubitemid 27387420)
18. Lesueur-Ginot L, Demarquay D, Kiss R, et al. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res 1999;59:2939-2943 (Pubitemid 29283135)
19. Bailly C, Lansiaux A, Dassonneville L, et al. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Biochemistry 1999;38:15556-15563 (Pubitemid 129503597)
20. Chauvier D, Morjani H, Manfait M. Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells. Breast Cancer Res Treat 2002;73:113-125 (Pubitemid 34548154)
21. Larsen AK, Gilbert C, Chyzak G, et al. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res 2001;61:2961-2967 (Pubitemid 32691941)
22. Demarquay D, Huchet M, Coulomb H, et al. The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison. Anticancer Drugs 2001;12:9-19 (Pubitemid 32142279)
23. Lavergne O, Demarquay D, Bailly C, et al. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J Med Chem 2000;43:2285-2289 (Pubitemid 30354554)
24. Lavergne O, Lesueur-Ginot L, Pla RF, et al. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem 1998;41:5410-5419 (Pubitemid 29031325)
25. Philippart P, Harper L, Chaboteaux C, et al. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin Cancer Res 2000;6:1557-1562 (Pubitemid 30226246)
26. Lansiaux A, Facompre M, Wattez N, et al. Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells. Mol Pharmacol 2001;60:450-461 (Pubitemid 32781551)
27. Liao Z, Robey RW, Guirouilh-Barbat J, et al. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Mol Pharmacol 2008;73:490-497 (Pubitemid 351159219)
28. Bates SE, Medina-Perez WY, Kohlhagen G, et al. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. J Pharmacol Exp Ther 2004;310:836-842 (Pubitemid 38988932)
29. Lavergne O, Demarquay D, Kasprzyk PG, et al. Homocamptothecins: E-ring modified CPT analogues. Ann NY Acad Sci 2000;922:100-111 (Pubitemid 32050245)
30. Lansiaux A, Bras-Goncalves RA, Rosty C, et al. Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11. Anticancer Res 2001;21:471-476 (Pubitemid 32267684)
31. De Cesare M, Zunino F, Pace S, et al. Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts. Eur J Cancer 2000;36:1558-1564 (Pubitemid 30619009)
32. Schaefer PL, Marks RS, Mahoney MR, et al. Randomized Phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. Am J Clin Oncol 2003;26:236-240 (Pubitemid 36712634)
33. Gelderblom H, Salazar R, Verweij J, et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res 2003;9:4101-4107 (Pubitemid 37204026)
34. Troconiz IF, Garrido MJ, Segura C, et al. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 2006;57:727-735
35. Scott L, Soepenberg O, Verweij J, et al. A multicentre Phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Ann Oncol 2007;18:569-575 (Pubitemid 46359641)
36. Lesimple T, Fumoleau P, Lortholary A, et al. First results of diflomotecan, a new topoisomerase inhibitor, as oral soft-gel capsules in a Phase I dose escalation study in patients with advanced malignant solid tumours. Eur j cancer suppl 2004;153-154
37. Loos WJ, Gelderblom H, Sparreboom A, et al. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 2000;6:2685-2689 (Pubitemid 30482104)
38. Xie R, Mathijssen RH, Sparreboom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 2002;20:3293-3301 (Pubitemid 34835675)
39. Mathijssen RH, Verweij J, de Jonge MJ, et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002;20:81-87 (Pubitemid 34032599)
40. Mould DR, Holford NH, Schellens JH, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002;71:334-348 (Pubitemid 34518144)
41. Schellens JH, Heinrich B, Lehnert M, et al. Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in Phase II studies. Invest New Drugs 2002;20:83-93 (Pubitemid 34251654)
42. Piscitelli SC, Rodvold KA, Rushing DA, et al. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 1993;53:555-561 (Pubitemid 23161203)
43. Gelderblom HA, de Jonge MJ, Sparreboom A, et al. Oral topoisomerase 1 inhibitors in adult patients: present and future. Invest New Drugs 1999;17:401-415 (Pubitemid 30135906)
44. Sparreboom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004;76:38-44 (Pubitemid 38844732)
45. Ipsen, data on file. 2008. Ref Type: Personal Communication
46. Teicher BA. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 2008;75:1262-1271 (Pubitemid 351305209)
47. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115 (Pubitemid 27021524)
48. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802 (Pubitemid 44450467)